Risk-reducing Strategies, Including Fimbriectomy, in Women With a Germline Mutation Predisposing to Ovarian or Pelvic Cancer

Starting soon · Not applicable

Conditions studied: Tubo-ovarian Carcinoma, High-grade Serous Carcinoma, Primary Peritoneal Carcinoma Stage III, Primary Peritoneal Carcinoma Stage IV, Primary Peritoneal Carcinoma

In brief

• FIMBRIMENOP-2402 study aims to evaluate the long-term management of cancer risks in premenopausal women who have a genetic predisposition to tubo-ovarian or primary peritoneal carcinoma, such as mutations in BRCA1, BRCA2, RAD51C, RAD51D, or PALB2 genes. This study offers an alternative to standard preventive surgery (bilateral salpingo-oophorectomy or BSO) by exploring the use of fimbriectomy (removal of the fallopian tube's fimbria) followed by delayed oophorectomy (removal of ovaries at menopause). It's a pragmatic multicenter trial conducted across various medical centers, employing a non-randomized controlled preference design to compare two preventive surgical strategies: 1. Fimbriectomy followed by delayed oophorectomy (F-DO). 2. Bilateral salpingo-oophorectomy (BSO). The primary objective is to compare the long-term efficacy of two preventive surgical strategies : 1. Fimbriectomy followed by delayed oophorectomy (F-DO). 2. Bilateral salpingo-oophorectomy (BSO). As for the design of the study, participants choose their preferred surgical strategy during or after oncogenetic counseling, ensuring patient autonomy in decision-making. • Follow-Up: Long-term follow-up includes clinical assessments, data collection from medical networks, and integration with national health databases to track outcomes up to the age of 70. This is the first French comparative study in real-world settings and is classified as interventional research (RIPH1) under French regulations, given the need to validate fimbriectomy efficacy.

Key facts

Study ID

NCT06726330

Run by

Centre Oscar Lambret

People needed

1100

Starts

2027-03-01

Expected to finish

2071-03-01

Last updated by the study team

2026-03-17

Who can join

Age: 35 and older, up to 50. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Woman between 35 to 50 years
• Addressed to or followed in an oncogenetic counselling
• Identified risk of tubo-ovarian or primary peritoneal carcinoma based on mutational status (BRCA1, BRCA 2, RAD51C, RAD51D, PALB2). The list of considered mutations may be extended during the study.
• Written informed consent
• Patient covered by the French "Social Security"

You may not qualify if…

• Prior bilateral oophorectomy and/or bilateral salpingectomy for any reason (prophylactic surgery or other)
• Personal history of ovarian, fallopian tube or primary peritoneal cancer
• Menopause defined by
• In women without prior chemotherapy If no prior hysterectomy: the absence of menses for at least 12 months, or FSH > 20 UI/L with low estrogen level with no identified gynecological or endocrine explanation. Amenorrhea related to an intrauterine device, vaginal ring or estrogen-progestin pill will not be considered as menopause.
• If prior hysterectomy: FSH >20 UI/L with low estrogen level (with or without vasomotor symptoms, genitourinary symptoms)
• In women with prior chemotherapy: the absence of menses for at least 24 months
• In all women with progesterone-loaded intra-uterine device (IUD): FSH > 20 UI/L with low estrogen level
• Inability to comply with medical follow-up of the trial (geographical, social or psychological reasons)
• Patient under guardianship or curatorship

Where it is running

• Centre Léon Bérard — Lyon, France, France
• Institut universitaire du cancer de Toulouse — Toulouse, France, France
• Centre Hospitalier de Valenciennes — Valenciennes, France, France
• Institut Bergonié — Bordeaux, France
• Centre François Baclesse — Caen, France
• Centre Jean Perrin — Clermont-Ferrand, France
• Centre Hospitalier Universitaire Dijon Bourgogne — Dijon, France
• Centre hospitalier universitaire Grenoble-Alpes — Grenoble, France
• Centre Hospitalier Universitaire de Lille — Lille, France
• Centre Oscar Lambret — Lille, France
• Clinique du Bois — Lille, France
• Institut Paoli-Calmettes — Marseille, France
• Institut de cancérologie de l'Ouest Centre René GAUDUCHEAU — Nantes, France
• Centre Antoine Lacassagne — Nice, France
• Gustave Roussy — Paris, France
• Hôpital de la Pitié Salpêtrière - AP-HP — Paris, France
• Hôpital Institut CURIE — Paris, France
• Hôpital Tenon AP-HP — Paris, France
• Institut Godinot — Reims, France
• Centre Henri Becquerel — Rouen, France
• Hôpitaux Privés Rouennais — Rouen, France
• Hôpital de Saint-Cloud — Saint-Cloud, France
• Hôpital Simone Veil - CH de Troyes — Troyes, France

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.